- Pacira BioSciences, Inc. Announces Pricing of $250.0 Million Aggregate Principal Amount of 2.125% Convertible Senior Notes due 2029
- Pacira BioSciences, Inc. Announces Proposed Offering of $250.0 Million Aggregate Principal Amount of Convertible Senior Notes
- Pacira BioSciences Reports First Quarter 2024 Financial Results and Announces $150 Million Share Repurchase program
- Pacira BioSciences to Participate in Fireside Chat at the 2024 RBC Capital Markets Global Healthcare Conference
- Pacira to Report First Quarter 2024 Financial Results on Tuesday May 7, 2024
- Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
- Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
- Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
- Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
- Pacira to Report 2023 Financial Results on Thursday February 29, 2024
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | -- |
Average volume | -- |
---|---|
Shares outstanding | 46.55m |
Free float | 45.96m |
P/E (TTM) | 22.91 |
Market cap | 1.38bn USD |
EPS (TTM) | 1.30 USD |
Data delayed at least 15 minutes.
More ▼